Table 2.

Modulation of T cell activation and antitumoral immune response by pericytes.

Pericyte type/origin	In vitro effect	Tumor model	In vivo effect	Reference
HBP	T cell adhesion, VCAM-mediated	N/A	N/A	(63)
HPP	T cell anergy	N/A	N/A	(64)
HRP, MRP	T cell inhibition, PDL1/IL-10-mediated	N/A	N/A	(93)
HPSC-derived PC, HBP, HPP	T cell hyporesponsivenes, induction of Tregs, PD-L1/TGFβ-mediated	N/A	N/A	(40)
C3H10T1/2-in vitro differentiated, tumor-conditioned PC; B16 tumor-derived PC	CD4+ T cell anergy, RGS5- and IL-6-dependent	B16 mouse melanoma	N/A	(94)
HBP	T cell anergy, PGE2-, NO-, HGF, TGFβ-mediated	Human malignant glioma	N/A	(95)
PDGF-B ret/ret mouse model (pericyte-deficient)	N/A	B16 melanoma, LLC mouse lung cancer	Recruitment of T-cell suppressive MDSC, IL-6 mediated. Increased tumor growth and metastasis	(96)
Rgs5−/− mouse model	N/A	RIP1-Tag5 (insulinoma) × Rgs5−/− mouse model	Vascular normalization and enhanced infiltration of CD8+ T cells. Increased survival	(97)
FVB/N mice	N/A	NT-2 mouse breast cancer	Increased infiltration of CD8+ cells after vaccination against pericyte antigens. Delayed tumor growth	(98)
C57BL/6, HDD (HLA-A2 transgenic) mice	N/A	MC38 mouse colon carcinoma, B16 melanoma	Increased infiltration of CD8+ cells after vaccination against pericyte antigens. Tumor eradication	(99)
SCID, C57BL/6, C57BL/6 IL-33−/− mice. Isolated LMP	PDGF-BB-induced IL-33 expression in LMP. Increased migration of IL-33-primed macrophages	pdgfb-shRNA A431 human epidermoid carcinoma, pdgfb-overexpressing murine T241 fibrosarcoma and LLC cells	Recruitment of TAM, IL-33 mediated. Metastasis promotion	(100)

HBP, human brain pericytes; HPP, human placental pericytes; HPSC, human pluripotent stem cells; HRP, human retinal pericytes; LLC, Lewis lung carcinoma; LMP, lung mouse pericytes; MDSC, myeloid-derived suppressor cells; MRP, mouse retinal pericytes; TAM, tumor-associated macrophages.